DelveInsight’s, “Malaria Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Malaria pipeline landscape. It covers the Malaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Malaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Malaria Pipeline Report

• DelveInsight’s Malaria pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Malaria treatment.
• The leading companies working in the Malaria Market include Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen, and others.
• Promising Malaria Pipeline Therapies in the various stages of development include KAE609, Coartem, BNT165b1, Fosmidomycin and Clindamycin co-administration, CHMI (NF135.C10), Ferroquine (SSR97193), Amodiaquine, and others.
• October 2023: BioNTech SE announced a study of Phase 1 clinical trials for BNT165b1. This first-in-human clinical trial, is a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, an ribonucleic acid (RNA)-lipid nanoparticle (LNP) encoding for part of the Plasmodium falciparum circumsporozoite protein (PfCSP). BNT165b1 will be evaluated at three dose levels (DLs) to select a safe and tolerable dose in a 3-dose schedule. The trial will enroll participants into three cohorts by dose level who will be randomized 4:1 to BNT165b1:placebo. The trial will use a staggered dose escalation schema with sentinel participants for Dose 1 in all cohorts.
• October 2023: Sanaria Inc. announced a study of Phase 2 clinical trials for Chloroquine chemoprophylaxis alone. The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in healthy Indonesian soldiers deployed to eastern Indonesia. The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in 372 healthy Indonesian soldiers aged 18-55 years who will be deployed in malarious eastern Indonesia.
• October 2023: GlaxoSmithKline announced a study of Phase 2 clinical trials for RTS,S/AS01E (1/5th dose). The study intends to establish proof of concept for a fractional dose schedule under conditions of natural exposure in children 5-17 months old at first vaccination. The study also aims to establish the role of third dose spacing in a fractional dose schedule, describe the effect of an earlier full fourth dose at Month 14 and describe the effect of multiple fractional or full yearly doses. The current study intends to establish proof of concept (POC) for a fractional dose schedule under conditions of natural exposure. The study will be conducted in children 5-17 months old at first vaccination living in areas of mid to high malaria transmission, in line with the age group recommended by the World Health Organization (WHO) for the implementation of the RTS,S/AS01E vaccine. Results from this study will be critical in informing future possibilities for the development of vaccine-based strategies which, in combination with other interventions, may contribute to the malaria elimination agenda.

 

Request a sample and discover the recent advances in Malaria Treatment Drugs @ Malaria Pipeline Report

 

In the Malaria Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malaria collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Malaria Overview

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites.

 

Find out more about Malaria Therapeutics Assessment @ Malaria Preclinical and Discovery Stage Products

 

Malaria Emerging Drugs Profile

• Cipargamin: Novartis

 

Malaria Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the Malaria therapies. The Malaria companies that have their Malaria drug candidates in the most advanced stage, i.e. Phase I include Novartis.

 

DelveInsight’s Malaria Pipeline Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

 

The malaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

 

Malaria Pipeline Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

 

Learn more about the emerging Malaria Pipeline Therapies @ Malaria Clinical Trials Assessment

 

Scope of the Malaria Pipeline Report

• Coverage- Global
• Malaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Malaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Malaria Companies- Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen, and others.
• Malaria Pipeline Therapies- KAE609, Coartem, BNT165b1, Fosmidomycin and Clindamycin co-administration, CHMI (NF135.C10), Ferroquine (SSR97193), Amodiaquine, and others.

 

Dive deep into rich insights for new drugs for Malaria Treatment, Visit @ Malaria Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Malaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malaria– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. PfSPZ Vaccine: Sanaria
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cipargamin: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Company name: Drug name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. INE963: Novartis
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Lotilaner: Tarsus Pharmaceuticals
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Malaria Key Companies
24. Malaria Key Products
25. Malaria- Unmet Needs
26. Malaria- Market Drivers and Barriers
27. Malaria- Future Perspectives and Conclusion
28. Malaria Analyst Views
29. Malaria Key Companies
30. Appendix

 

For further information on the Malaria Pipeline therapeutics, reach out to Malaria Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting